Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
69.35 EUR | +0.43% | +3.51% | +103.97% |
Sales 2024 * | 123M 133M | Sales 2025 * | 325M 353M | Capitalization | 2.61B 2.84B |
---|---|---|---|---|---|
Net income 2024 * | -430M -467M | Net income 2025 * | -116M -126M | EV / Sales 2024 * | 22 x |
Net Debt 2024 * | 89.28M 97.02M | Net cash position 2025 * | 94.69M 103M | EV / Sales 2025 * | 7.74 x |
P/E ratio 2024 * |
-6.14
x | P/E ratio 2025 * |
-33.3
x | Employees | 464 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.39% |
Latest transcript on MorphoSys AG
1 day | +0.43% | ||
1 week | +3.51% | ||
Current month | +4.76% | ||
1 month | +2.44% | ||
3 months | +5.97% | ||
6 months | +214.09% | ||
Current year | +103.97% |
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.44% | 125 M€ | -.--% | ||
0.80% | 17 M€ | -.--% | - | |
0.11% | 2 M€ | -.--% | ||
0.02% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 69.35 | +0.43% | 193,986 |
24-05-16 | 69.05 | +1.62% | 349,856 |
24-05-15 | 67.95 | +0.15% | 20,528 |
24-05-14 | 67.85 | +0.74% | 88,740 |
24-05-13 | 67.35 | +0.52% | 114,813 |
Delayed Quote Xetra, May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.97% | 2.84B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- MOR Stock